Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Halozyme entered a global licensing agreement with GSK to utilize its ENHANZE drug delivery technology for subcutaneous formulations of oncology targets, including antibody drug conjugates (ADCs). The collaboration includes an upfront payment, future milestones, and royalties on net sales, marking the first time ENHANZE has been applied to ADCs.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.